NS-2359

Chemical compound
  • none
Identifiers
  • (1R,2R,3S,5S)-3-(3,4-dichlorophenyl)-2-(methoxymethyl)-8-azabicyclo[3.2.1]octane
PubChem CID
  • 11408320
UNII
  • 76H76554PA
Chemical and physical dataFormulaC15H19Cl2NOMolar mass300.22 g·mol−13D model (JSmol)
  • Interactive image
  • Clc1ccc(cc1Cl)C(C2COC)CC3NC2CC3
  (verify)

NS-2359 (GSK-372475) is a serotonin-norepinephrine-dopamine reuptake inhibitor. It was under development by GlaxoSmithKline (GSK) as an antidepressant,[1] but was discontinued in 2009 when phase II clinical trials showed the drug was not effective and not well tolerated.[2] The results did not support further effort by the company.[1] NS-2359 was also in clinical trials for the treatment of ADHD,[3] phase II having been completed in 2007.[4] A phase I clinical trial exploring the effect of NS-2359 on cocaine-dependent individuals was completed in 2002.[5]

See also

  • Tesofensine

References

  1. ^ a b "NeuroSearch announces the results of Phase II Proof of Concept studies with NS2359 in depression". NeuroSearch.
  2. ^ Learned S, Graff O, Roychowdhury S, Moate R, Krishnan KR, Archer G, Modell JG, Alexander R, Zamuner S, Lavergne A, Evoniuk G, Ratti E (May 2012). "Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trials". Journal of Psychopharmacology. 26 (5): 653–62. doi:10.1177/0269881111424931. PMID 22048884. S2CID 9365152.
  3. ^ Wilens TE, Klint T, Adler L, West S, Wesnes K, Graff O, Mikkelsen B (June 2008). "A randomized controlled trial of a novel mixed monoamine reuptake inhibitor in adults with ADHD". Behavioral and Brain Functions. 4: 24. doi:10.1186/1744-9081-4-24. PMC 2442604. PMID 18554401.
  4. ^ Clinical trial number NCT00467428 for "Efficacy and Safety of NS2359 in Adults With Attention Deficit Hyperactivity Disorder" at ClinicalTrials.gov
  5. ^ Clinical trial number NCT00032916 for "Interaction Study With NS2359 and Cocaine in Cocaine Experienced Volunteers" at ClinicalTrials.gov
  • v
  • t
  • e
DATTooltip Dopamine transporter
(DRIsTooltip Dopamine reuptake inhibitors)
NETTooltip Norepinephrine transporter
(NRIsTooltip Norepinephrine reuptake inhibitors)
SERTTooltip Serotonin transporter
(SRIsTooltip Serotonin reuptake inhibitors)
VMATsTooltip Vesicular monoamine transportersOthers
See also: Receptor/signaling modulators • Monoamine releasing agents • Adrenergics • Dopaminergics • Serotonergics • Monoamine metabolism modulators • Monoamine neurotoxins
  • v
  • t
  • e
2-Carboxymethyl Esters
(3,4-Disubstituted Phenyl)-tropanes
Arylcarboxy
Carboxyalkyl
Acyl
  • PTT/WF-11
  • WF-23
  • PIT/WF-21
  • WF-33
β,α Stereochemistry
α,β Stereochemistry
Heterocycles: 3-Substituted-isoxazol-5-yl
Heterocycles: 3-Substituted-1,2,4-oxadiazole
N-alkyl
  • FP-β-CPPIT
  • FE-β-CPPIT
  • Altropane
  • Ioflupane (123I)
N-replaced (S,O,C)
Irreversible
Nortropanes (N-demethylated)
  • NS2359 (GSK-372,475)
Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

  • v
  • t
  • e